Riabni® is the only rituximab biosimilar that provides the Amgen level of support to your patients and practice
RIABNI® is FDA approved for all Rituxan® oncology indications1,2
Non-Hodgkin's lymphoma (NHL)
- - Follicular lymphoma (FL)
- - Previously untreated large B-cell lymphoma
- - Non-progressing (stable disease)
- Previously untreated chronic lymphocytic leukemia (CLL)
- FDA = Food and Drug Administration.